摘要
目的：探讨硒酵母片（西维尔）对肾功能正常的2型糖尿病肾病患者尿微量白蛋白的影响。方法：以晨尿的尿微量白蛋白/肌酐比值定义微量白蛋白尿（microalbuminuria,UMALB）,UMALB〈30μg/g Cr为无微量白蛋白尿,UMALB≥30mg/g Cr为微量白蛋白尿,连续2次可以诊断为糖尿病肾病。以肾小球滤过率估算值（Estimated glomerular filtration rate,e GFR）作为肾功能的评价指标（e GFR 80-100m L/min·1.73m^2为肾功能正常）,将67例肾功能正常的2型糖尿病肾病患者分为西维尔观察组29例和对照组38例,用t检验分析比较了治疗前后两组间的临床资料和实验室检查,P〈0.05为差异有统计学意义。结果：治疗前,两组尿微量白蛋白无显著性差异,治疗后6个月,观察组的尿微量白蛋白（326.9±101.7）mg/g Cr低于对照组（349.6±115.4）mg/g Cr,差异有统计学意义（P〈0.05）。结论：西维尔可降低2型糖尿病肾病患者尿微量白蛋白水平,延缓2型糖尿病患者糖尿病肾病的进展。
Objective： To discuss the effects of selenium yeast tablets on microalbuminuria of type 2 diabetes with normoal eGFR. Methods： Microalbuminuria above 30mg/gCr was defined as abnormal. The patients whoes microalbumin-uria were abnaomal for twice continuously with type 2 diabetes were diagnosed as diabetic nephropathy, the renal functions were estimated with the estimated glomerular filtration rate（eGFR, 80-100ml/min·1.73m^2 is normal） and clinical data were recorded. The patients with diabetic nephropathy whose eGFR were normal were divided into the treatment group （n=29） with selenium yeast tablets and control group （n=38）.Then the microalbuminuria and other clinical data were compared by T-test with SPSS19.0. Results： There was not distinct difference betweet the two groups at the beginning. The microalbu-minuria in the treatment group was lower than that of in the control group（P=0.023） after treatment. Conclusions： The se-lenium yeast tablets can reduce the microalbuminuria of type 2 diabetes with diabetic nephropathy and delay the deteriora-tion of diabetic nephropathy.
出处
《交通医学》
2014年第5期442-444,448,共4页
Medical Journal of Communications
